Shares of Ultragenyx Pharmaceutical (RARE) are surging 5.53% in pre-market trading on Wednesday, as investors react positively to recent analyst recommendations. The biotechnology company, which focuses on developing novel products for rare and ultra-rare diseases, is seeing increased interest from Wall Street.
The stock's upward movement comes on the heels of two bullish analyst reports. Barclays analyst Gena Wang reiterated a Buy rating on Ultragenyx Pharmaceutical, signaling confidence in the company's prospects. Additionally, Wells Fargo analyst Tiago Fauth also maintained a Buy rating on RARE stock. These positive assessments from reputable financial institutions are likely fueling investor optimism and contributing to the pre-market rally. As the market opens, investors will be watching closely to see if Ultragenyx can maintain this momentum throughout the trading session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.